Inhibrx Q1 EPS $(0.80) Down From $(0.51) YoY
Inhibrx (NASDAQ:INBX) reported quarterly losses of $(0.80) per share. This is a 56.86 percent decrease over losses of $(0.51) per share from the same period last year.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
Inhibrx To Present INBRX-101 Data At ATS 2022 Annual Meeting May 13-18
Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that late-breaking data from INBRX-101 will be presented at the
SMBC Nikko Initiates Coverage On Inhibrx with Outperform Rating, Announces Price Target of $40
SMBC Nikko initiates coverage on Inhibrx (NASDAQ:INBX) with a Outperform rating and announces Price Target of $40.
Mid-Morning Market Update: Markets Open Lower; Johnson & Johnson Sales Miss Views
Following the market opening Tuesday, the Dow traded down 1.79% to 33,748.82 while the NASDAQ fell 2.56% to 13,499.97. The S&P also fell, dropping, 2.59% to 13,496.29.
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours.
Credit Suisse Maintains Outperform on Inhibrx, Raises Price Target to $53
Credit Suisse analyst Judah Frommer maintains Inhibrx (NASDAQ:INBX) with a Outperform and raises the price target from $44 to $53.
JMP Securities Maintains Market Outperform on Inhibrx, Raises Price Target to $53
JMP Securities analyst Reni Benjamin maintains Inhibrx (NASDAQ:INBX) with a Market Outperform and raises the price target from $46 to $53.
